We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
New Tymbal Resources Ltd | TSXV:NTB | TSX Venture | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.02 | 0.01 | 0.02 | 0 | 01:00:00 |
Editors Note: There is a photo associated with this press release.
On October 25, 2010 The Howard Group hosted its 2nd "Opportunity Knocks" investor conference in Calgary. Dr. Tina Sampalis, Chief Scientific Officer of Neptune provided an overview of the company to an audience of investment advisors & private investors.
A recording of the presentation is now available online. Click here to view - http://www.howardgroupinc.com/conference2010.html
Highlights on Neptune are as follows:
-- First half F2011 revenues rose 95% to over $8 million versus F2010 first half. -- Earnings and EBITDA positive. -- Key announcements on animal studies supporting extreme effectiveness on cholesterol related issues. -- Expect pending approval from health regulatory bodies that will facilitate Phase II clinical studies -- Bayer expected to launch major roll-out of Arctic Wonder (Neptune) dietary supplement in Q1/2011.
About Neptune Technologies & Bioressources Inc.
Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 20 countries worldwide.
To view the photo associated with this release, please visit the following link: http://www.marketwire.com/library/20101109-1109tina_800.jpg
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contacts: Neptune Tech & Bioressources Andre Godin VP Administration & Finance (450) 687-2262 (450) 687-2272 (FAX) a.godin@neptunebiotech.com www.neptunebiotech.com The Howard Group Inc. Bob Beaty Investor Relations (403) 221-0915 or Toll free: (888) 221-0915 info@howardgroupinc.com www.howardgroupinc.com
1 Year New Tymbal Resources Chart |
1 Month New Tymbal Resources Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions